AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32003141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4153
Study 35387672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting mortality
Number of subjects: 767
Study 35387672 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate Cox regression analysis
Number of subjects: 767
Study 34071485 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched yogurt with PAF inhibitors from olive pomace
Number of subjects: 92
Study 34071485 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 34091818 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 Hz spinal cord stimulation
Number of subjects: 32
Study 34091818 — intervention group
Group type: COMPARATOR
Intervention: 30 Hz spinal cord stimulation
Number of subjects: 32
Study 34091818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stimulation strategies (1000 Hz and 30 Hz)
Number of subjects: 32
Study 32105518 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 246
Study 32105518 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 246
Study 35774049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (ARNI)
Number of subjects: 106
Study 35774049 — intervention group
Group type: COMPARATOR
Intervention: Standard optimal medical therapy (OMT)
Number of subjects: 106
Study 32959589 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative acupoint application therapy
Number of subjects: 105
Study 32959589 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative acupoint application therapy
Number of subjects: 105
Study 32959589 — intervention group
Group type: COMPARATOR
Intervention: Control group (ERAS interventions)
Number of subjects: 105
Study 35738653 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT with oNCRT
Number of subjects: 115
Study 35738653 — intervention group
Group type: COMPARATOR
Intervention: PCT only
Number of subjects: 115
Study 35679432 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetables only (veg‐only, n = 61)
Number of subjects: 117
Study 35679432 — intervention group
Group type: COMPARATOR
Intervention: Control (fruit and vegetables, n = 56)
Number of subjects: 117
Study 33774892 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Health care (IHC)
Number of subjects: 49
Study 33774892 — intervention group
Group type: COMPARATOR
Intervention: Conventional health care (controls)
Number of subjects: 49
Study 32727420 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual postnatal care plus a maternal suicide prevention program (intervention group)
Number of subjects: 464
Study 32727420 — intervention group
Group type: COMPARATOR
Intervention: Usual postnatal care alone (control group)
Number of subjects: 464
Study 35737006 — intervention group
Group type: EXPERIMENTAL
Intervention: LLS‐TLH
Number of subjects: 80
Study 35737006 — intervention group
Group type: COMPARATOR
Intervention: LSC‐TLH
Number of subjects: 80
Study 33590850 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic enlargement
Number of subjects: 387
Study 33590850 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus attenuation score ≥ 2
Number of subjects: 387
Study 33590850 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus attenuation score
Number of subjects: 387
Study 32476183 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by fluorouracil, doxorubicin, and cyclophosphamide (T-FAC)
Number of subjects: 0
Study 32476183 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, doxorubicin, and cyclophosphamide followed by docetaxel (FAC-T)
Number of subjects: 0
Study 34570182 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) results provided early (15 days after enrollment)
Number of subjects: 354
Study 34570182 — intervention group
Group type: COMPARATOR
Intervention: Whole-genome sequencing (WGS) results provided delayed (60 days after enrollment)
Number of subjects: 354
Study 34570182 — intervention group
Group type: COMPARATOR
Intervention: Delayed group at 90 days
Number of subjects: 354
Study 34570182 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall COMs across the observation window
Number of subjects: 354
Study 34570182 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay and survival
Number of subjects: 354
Study 33000690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐MAST programme (n=8)
Number of subjects: 14
Study 33000690 — intervention group
Group type: COMPARATOR
Intervention: Standard care/waitlist (n=6)
Number of subjects: 14
Study 32703800 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiopen areas in hospitality venues
Number of subjects: 3253
Study 32703800 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiopen areas in higher education centres
Number of subjects: 3253
Study 32703800 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor areas in health centres
Number of subjects: 3253
Study 32703800 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor areas in schools
Number of subjects: 3253
Study 32703800 — intervention group
Group type: COMPARATOR
Intervention: Enclosed areas
Number of subjects: 3253
Study 35342752 — intervention group
Group type: EXPERIMENTAL
Intervention: Dycal
Number of subjects: 70
Study 35342752 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraCal LC
Number of subjects: 70
Study 35342752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime-Lite
Number of subjects: 70
Study 35342752 — intervention group
Group type: EXPERIMENTAL
Intervention: Activa BioActive
Number of subjects: 70
Study 35342752 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 70
Study 35342752 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC
Number of subjects: 70
Study 35342752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no liner pretreatment)
Number of subjects: 70
Study 33548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 10, received 30-45 min of training)
Number of subjects: 20
Study 33548586 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10, no intervention)
Number of subjects: 20
Study 33548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (tested immediately after intervention)
Number of subjects: 20
Study 33548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (retested one month after intervention)
Number of subjects: 20
Study 35186238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (PE group)
Number of subjects: 48
Study 35186238 — intervention group
Group type: COMPARATOR
Intervention: Iliac fascia block (FI group)
Number of subjects: 48
Study 35732390 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual self-conversation using the ConVRself platform
Number of subjects: 96
Study 35732390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-established discourse provided by the virtual counsellor
Number of subjects: 96
Study 35732390 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 96
Study 33327695 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker flex tip (PFT) ETT
Number of subjects: 58
Study 33327695 — intervention group
Group type: COMPARATOR
Intervention: Unoflex reinforced (UFR) ETT
Number of subjects: 58
Study 35286431 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified warm gas without forced air warming blanket (HUMI)
Number of subjects: 150
Study 35286431 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified warm gas combined with forced air warming blanket (HUMI+)
Number of subjects: 150
Study 35286431 — intervention group
Group type: COMPARATOR
Intervention: Non-warmed, non-humidified CO2 with forced air warming blanket (AIR)
Number of subjects: 150
Study 34436536 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg orally once daily) plus Letrozole (2.5 mg orally once daily)
Number of subjects: 199
Study 34436536 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (2.5 mg orally once daily)
Number of subjects: 199
Study 36271335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral esomeprazole 20 mg, twice-daily for 36 weeks (Group D)
Number of subjects: 120
Study 36271335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral esomeprazole 20 mg, once-daily for 36 weeks (Group S)
Number of subjects: 120
Study 36271335 — intervention group
Group type: COMPARATOR
Intervention: PPI-on-demand (n=32)
Number of subjects: 120
Study 36271335 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, n=135)
Number of subjects: 120
Study 32174352 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ice-based cooling vest (PCM)
Number of subjects: 8
Study 32174352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slushy consumed before work combined with ice-based cooling vest (SLIV)
Number of subjects: 8
Study 32174352 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable battery-operated water-perfused suit (WPS)
Number of subjects: 8
Study 32174352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-based cooling vest (IV)
Number of subjects: 8
Study 32174352 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling)
Number of subjects: 8
Study 35314817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 5 min before intercourse
Number of subjects: 91
Study 35314817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 15 min before intercourse
Number of subjects: 91
Study 35314817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 30 min before intercourse
Number of subjects: 91
Study 35314817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortacin™ (prilocaine/lidocaine spray) - 1 spray administered 5 min before intercourse
Number of subjects: 91
Study 35314817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortacin™ (prilocaine/lidocaine spray) - 5 sprays administered 5 min before intercourse
Number of subjects: 91
Study 33080734 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposely seeking polyps (Group A)
Number of subjects: 419
Study 33080734 — intervention group
Group type: COMPARATOR
Intervention: Routine examination (Group B)
Number of subjects: 419
Study 33080734 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposely seeking polyps (Group AR-1)
Number of subjects: 419
Study 33080734 — intervention group
Group type: COMPARATOR
Intervention: Routine examination (Group BR-1)
Number of subjects: 419
Study 35439631 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized aerobic training (8-week program, 30-40 min/day, 5 days/week)
Number of subjects: 140
Study 33811367 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 1 mg
Number of subjects: 106
Study 33811367 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 2 mg
Number of subjects: 106
Study 33811367 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 106
Study 33811367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 33160341 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention methods (including condoms and daily oral PrEP)
Number of subjects: 38
Study 33160341 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable formulations (e.g., vaccines, passive antibodies, chemoprophylaxis)
Number of subjects: 38
Study 36071005 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-focus NBI (group A)
Number of subjects: 362
Study 36071005 — intervention group
Group type: COMPARATOR
Intervention: Normal-focus NBI (group B)
Number of subjects: 362
Study 36071005 — intervention group
Group type: EXPERIMENTAL
Intervention: WASP criteria
Number of subjects: 362
Study 32771456 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-endocycloplasty (ECPL)
Number of subjects: 39
Study 32771456 — intervention group
Group type: COMPARATOR
Intervention: Phacotrabeculectomy
Number of subjects: 39
Study 34164496 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated frequency-doubled 1,064/532 nm picosecond Nd:YAG laser
Number of subjects: 22
Study 34164496 — intervention group
Group type: COMPARATOR
Intervention: Non-ablative fractional 1,540 nm Er: glass laser
Number of subjects: 22
Study 33389233 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education alerts through the Family Medicine Study Guide mobile app
Number of subjects: 634
Study 33389233 — intervention group
Group type: COMPARATOR
Intervention: Control group with the same app but no alerts
Number of subjects: 634
Study 35256248 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 49
Study 35256248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 34126630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cranberry beverage (HCb; 480 mL)
Number of subjects: 171
Study 34126630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose and low-dose cranberry beverages (HCb and LCb)
Number of subjects: 171
Study 34126630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cranberry beverage (LCb; 240 mL cranberry beverage plus 240 mL placebo)
Number of subjects: 171
Study 34126630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (480 mL)
Number of subjects: 171
Study 32576084 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib at full dose
Number of subjects: 3843
Study 32576084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib at full dose
Number of subjects: 3843
Study 32576084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib at reduced dose (400 mg)
Number of subjects: 3843
Study 32576084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib at reduced dose (200 mg)
Number of subjects: 3843
Study 32576084 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib at full dose
Number of subjects: 3843
Study 32576084 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib at reduced dose
Number of subjects: 3843
Study 32576084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (overall)
Number of subjects: 3843
Study 35273272 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable footwear (UF)
Number of subjects: 23
Study 35273272 — intervention group
Group type: COMPARATOR
Intervention: Stable footwear (SF)
Number of subjects: 23
Study 33727798 — intervention group
Group type: COMPARATOR
Intervention: Benfotiamine (150–1200 mg single ascending doses)
Number of subjects: 28
Study 33727798 — intervention group
Group type: COMPARATOR
Intervention: Benfotiamine (150, 300, or 600 mg multiple ascending doses)
Number of subjects: 28
Study 33727798 — intervention group
Group type: COMPARATOR
Intervention: Benfotiamine
Number of subjects: 28
Study 35443250 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy agers (HA)
Number of subjects: 1889
Study 35443250 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HA but not pre-frail
Number of subjects: 1889
Study 35443250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail or frail
Number of subjects: 1889
Study 35443250 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health state transition
Number of subjects: 1889
Study 35443250 — intervention group
Group type: EXPERIMENTAL
Intervention: Age effect on health state improvement
Number of subjects: 1889
Study 35443250 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender effect on health state trajectory
Number of subjects: 1889
Study 32909208 — intervention group
Group type: COMPARATOR
Intervention: New LigaSure™ devices
Number of subjects: 168
Study 32909208 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprocessed LigaSure™ devices
Number of subjects: 168
Study 32980559 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (ear seeds placed on shoulders and muscle relaxation points from 2 hours before surgery until 24 hours after surgery)
Number of subjects: 90
Study 35532997 — intervention group
Group type: EXPERIMENTAL
Intervention: Promised airtime incentive of 50 BDT (US $0.60) or 5000 UGX (US $1.35)
Number of subjects: 1165
Study 35532997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive (500 BDT and 100,000 UGX)
Number of subjects: 1165
Study 35532997 — intervention group
Group type: COMPARATOR
Intervention: No incentive (control)
Number of subjects: 1165
Study 32287110 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent cap-assisted choledochoscopy (Group B)
Number of subjects: 100
Study 32287110 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic choledochoscopy without transparent cap (Group A)
Number of subjects: 100
Study 35343882 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 2
Study 35343882 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 2
Study 34271974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms developed from multivariable logistic regressions for predicting 1-year mortality
Number of subjects: 702
Study 34271974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms developed from multivariable logistic regressions for predicting walking ability
Number of subjects: 702
Study 35397576 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 690
Study 35397576 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy
Number of subjects: 690
Study 34051386 — intervention group
Group type: EXPERIMENTAL
Intervention: AADI extrapolated from AADI/O and AADI/C2 ratios
Number of subjects: 119
Study 34051386 — intervention group
Group type: EXPERIMENTAL
Intervention: PADI extrapolated from PADI/O and PADI/C2 ratios
Number of subjects: 119
Study 36300646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inarigivir 25 mg
Number of subjects: 80
Study 36300646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inarigivir 50 mg
Number of subjects: 80
Study 36300646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inarigivir 100 mg
Number of subjects: 80
Study 36300646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inarigivir 200 mg
Number of subjects: 80
Study 36300646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36300646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inarigivir (all doses)
Number of subjects: 80
Study 36300646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inarigivir (all doses) during tenofovir treatment
Number of subjects: 80
Study 36300646 — intervention group
Group type: COMPARATOR
Intervention: Placebo during tenofovir treatment
Number of subjects: 80
Study 36300646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inarigivir
Number of subjects: 80
Study 33839277 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked Color Imaging (LCI)
Number of subjects: 700
Study 33839277 — intervention group
Group type: COMPARATOR
Intervention: White Light Imaging (WLI)
Number of subjects: 700
Study 34297735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hugvie (huggable device)
Number of subjects: 24
Study 34297735 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone only (Control)
Number of subjects: 24
Study 35901492 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training
Number of subjects: 218
Study 35901492 — intervention group
Group type: COMPARATOR
Intervention: Control (safety information)
Number of subjects: 218
Study 34462990 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal cash transfers (intervention)
Number of subjects: 0
Study 34462990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36092972 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS delivered 3x/week for 8 weeks
Number of subjects: 51
Study 36092972 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation delivered 3x/week for 8 weeks
Number of subjects: 51
Study 32304540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% autologous serum eye drops
Number of subjects: 60
Study 32304540 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 60
Study 36039002 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use in Black or African descent residents
Number of subjects: 336
Study 36039002 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant use in White residents
Number of subjects: 336
Study 32005073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 32005073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33574660 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 0
Study 32502795 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater gait training
Number of subjects: 21
Study 32502795 — intervention group
Group type: COMPARATOR
Intervention: Overground gait training
Number of subjects: 21
Study 33810379 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital smile designed computer-aided 'All on Four' rehabilitation
Number of subjects: 50
Study 33810379 — intervention group
Group type: COMPARATOR
Intervention: Traditional 'All on Four' technique
Number of subjects: 50
Study 33810379 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital protocol
Number of subjects: 50
Study 33810379 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol
Number of subjects: 50
Study 33810379 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital method
Number of subjects: 50
Study 32657611 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-T (4 cycles of epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2, followed by 4 cycles of docetaxel 75 mg/m2)
Number of subjects: 280
Study 32657611 — intervention group
Group type: COMPARATOR
Intervention: TCb (6 cycles of docetaxel 75 mg/m2 + carboplatin AUC 6)
Number of subjects: 280
Study 32657611 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-T
Number of subjects: 280
Study 32657611 — intervention group
Group type: COMPARATOR
Intervention: TCb
Number of subjects: 280
Study 33239518 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical recovery
Number of subjects: 198
Study 33239518 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related recovery
Number of subjects: 198
Study 33239518 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability benefits
Number of subjects: 198
Study 35430924 — intervention group
Group type: EXPERIMENTAL
Intervention: Yarrow liver compresses
Number of subjects: 20